Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Bücklein V, et al. Among authors: iacoboni g. Hemasphere. 2023 Jul 11;7(8):e907. doi: 10.1097/HS9.0000000000000907. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37449196 Free PMC article.
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Carpio C, et al. Among authors: iacoboni g. Leuk Lymphoma. 2021 Sep;62(9):2288-2291. doi: 10.1080/10428194.2021.1913141. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33899648 No abstract available.
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GELTAMO Spanish Groups. Iacoboni G, et al. Cancer Med. 2021 May;10(10):3214-3223. doi: 10.1002/cam4.3881. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932100 Free PMC article.
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Iacoboni G, et al. Blood Adv. 2022 Jun 28;6(12):3606-3610. doi: 10.1182/bloodadvances.2021006922. Blood Adv. 2022. PMID: 35271707 Free PMC article. No abstract available.
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: iacoboni g. J Immunother Cancer. 2022 May;10(5):e004475. doi: 10.1136/jitc-2021-004475. J Immunother Cancer. 2022. PMID: 35580927 Free PMC article.
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.
Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Bücklein V, Trenker C, Hernani R, Naumann R, Schäfer J, Blumenberg V, Schmidt C, Sohlbach K, von Bergwelt-Baildon M, Bachy E, Barba P, Subklewe M. Rejeski K, et al. Among authors: iacoboni g. Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776. Blood Adv. 2022. PMID: 35793454 Free PMC article. No abstract available.
50 results